F. De Vita et al., Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients, CHEST, 117(2), 2000, pp. 365-373
Citations number
29
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Study objective: To investigate the prognostic significance of interleukin
(IL)-10 serum levels in advanced non-small cell lung cancer (NSCLC) patient
s.
Design: IL-10 serum levels were measured before chemotherapy, on completion
of therapy, and at follow-up by means of a commercially available enzyme-l
inked immunoassay. The results were then analyzed in comparison with other
prognostic variables, and a model predicting overall survival (OS) and time
to treatment failure (TTF) was finally generated.
Setting: University hospital.
Patients: Sixty consecutive patients with TNM stage III or IV NSCLC undergo
ing conventional platinum-based regimens.
Results: Elevated levels of serum IL-10 were found in cancer patients with
respect to healthy control subjects (17.7 +/- 4.4 vs 9.2 +/- 1.5 pg/mL, res
pectively; p < 0.05), with patients with metastatic disease showing signifi
cantly higher levels than patients with undisseminated cancer (21.0 +/- 4.2
vs 14.3 +/- 1.2 pg/mL, respectively; p < 0.05). Following completion of tr
eatment, patients were classified as responders if they had achieved either
one of the following: complete response, pal tial response, or stable dise
ase; and nonresponders, in case of progressive disease. Retrospective analy
sis of basal IL-10 serum levels in these two subgroups showed a significant
difference between responders and nonresponders (15.2 +/- 2.2 vs 21.4 +/-
4.2 pg/mL, respectively; p < 0.05). Moreover, a further significant increas
e in IL-10 serum levels was observed in nonresponders at the end of therapy
(21.4 +/- 4.2 vs 26.0 +/- 4.3 pg/mL, prechemotherapy and postchemotherapy,
respectively; p < 0.05), whereas values in responders were found to have s
ignificantly decreased (15.2 +/- 2.2 vs 14.8 +/- 2.2 pg/mL, prechemotherapy
and postchemotherapy, respectively; p < 0.05). Using univariate and multiv
ariate analyses, both OS and TTF were shown to be affected by the mean path
ologic levels of IL-10. Stepwise regression analysis identified IL-10 serum
level and stage as the prognostic factors related to OS, and IL-10 serum l
evel and performance status as the prognostic factors related to TTF.
Conclusions: In conclusion, this study shows that the measurement of pretre
atment IL-10 serum levels is of independent prognostic utility in patients
with NSCLC and may be useful for detection of disease progression.